Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Yasutoshi Kuboki et al.|Cancer Research|2023Cited by 37
Responsiveness of different MET tumour alterations to type I and type II MET inhibitorsYonina R. Murciano‐Goroff, Emiliano Cocco|Clinical and Translational Medicine|2025Cited by 2